Growth Capitalist (https://growthcapitalist.com/tag/biotech/page/73/)
BioDelivery Sciences International, Inc. (BDSI) announced that it has raised $60,000,000 in a Registered Direct transaction. The common stock was sold at $8.00 per share, an approximate 3% discount to the market price ($8.26) of BDSI at deal announcement. Roth Capital Partners acted as agent on the deal. The investment was led by Federated Kaufmann. Issuer counsel was Ellenoff Grossman & Schole.
NanoViricides (NNVC), a biotech company that has raised $42 million through PIPE and registered equity private placements in the last 12 months, including a $20 million registered direct offering managed by Midtown Partners and Chardan Capital Markets in late January, experienced a hit of up to 28% in its stock on Tuesday, Feb. 11, after an anonymous short seller published a research note questioning how company assets are being spent by executives. Growth Capital Investor reported in October on many of the issues raised in the Seeking Alpha article, which included discrepancies in their public filings. The company briefly halted the small cap stock mid-day and held a conference call on a small internet radio station called Yorba Media calling the article “baseless and inaccurate.”
NanoViricides, headed up by Eugene Seymour and Anil Diwan, claims to be creating special purpose nano-materials for viral therapy. The company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, oral and genital herpes, viral diseases of the eye including EKC and herpes keratitis, hepatitis C, rabies, Dengue fever, and Ebola virus, among others.
Pressure BioSciences, Inc. (PBIO) announced that it has raised $1,398,044 in a Convertible Preferred Stock transaction. The fixed conversion price of the Convertible Preferred Stock is $0.25 per share, an approximate 7.41% discount to the market price ($0.27) of PBIO at deal announcement. A series of 2,796,000 36-Month Warrants with an exercise price of $0.31 per share (15.74% premium) was issued to the investors in this transaction. Issuer counsel was Szaferman Lakind Blumstein & Blader, PC. This Placement funded in tranches.
MELA Sciences Inc. (MELA) announced that it has raised $12,450,000 in a Convertible Preferred Stock transaction. The fixed conversion price of the Convertible Preferred Stock is $0.84 per share, an approximate 12.46% premium to the market price ($0.75) of MELA at deal announcement. A series of 13,297,29 60-Month Warrants with an exercise price of $0.74 per share (0.92382% discount) was issued to the investors in this transaction. Craig-Hallum Capital Group LLC acted as the exclusive agent on the transaction. The investors were Broadfin Capital and Sabby Management. In conjunction with the financing, The Company’s directors have agreed to purchase $150,000 in restricted common stock priced at $0.74 per share.
